Oralair

Allergen Extract from Pollen of Dactylis glomerata, Anthoxanthum odoratum, Lolium perenne, Poa pratensis, the active ingredient in Oralair, is a allergen immunotherapy presented as a sublingual tablet for sublingual use. It treats seasonal allergic rhinitis and allergic rhinoconjunctivitis caused by grass pollen in patients with documented sensitivity.

GNH USA supplies Oralair as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oralair is indicated for grass‑pollen related allergic conditions and works through allergen‑specific immunotherapy. - Seasonal allergic rhinitis (grass pollen): reduces nasal congestion, sneezing, itching and watery eyes. - Grass‑pollen‑induced allergic rhinoconjunctivitis: improves both nasal and ocular symptoms. - Documented grass‑pollen allergy: provides long‑term immune tolerance to reduce symptom severity over the pollen season.

Oralair may cause local and systemic reactions.

Common Side Effects: - Oral itching or tingling. - Throat irritation or mild swelling. - Ear itching. - Mild gastrointestinal discomfort. - Headache. - Transient cough.

Serious or Rare Side Effects: - Anaphylaxis or severe systemic allergic reaction. - Severe oral or facial edema. - Urticaria (hives). - Angioedema affecting airway. - Respiratory distress or bronchospasm. - Cardiovascular collapse.

Before initiating therapy, consider the following precautions. - Contraindication: known hypersensitivity to the product or its excipients. - Severe uncontrolled asthma: avoid use until asthma is well‑controlled. - Acute allergic episode: postpone dosing during active severe symptoms. - Pregnancy and breastfeeding: safety not established; discuss with a healthcare professional. - Concomitant immunotherapy: monitor for additive allergen exposure. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Oralair may interact with other medications; monitor as indicated.

Major Interactions (Avoid): - Beta‑blockers: may blunt response to emergency treatment of anaphylaxis. - ACE inhibitors: may increase risk of angioedema.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask local side effects, adjust observation. - Systemic corticosteroids: may reduce observable efficacy of immunotherapy. - Other allergen immunotherapies: cumulative allergen load may increase reaction risk.